UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated January 11, 2018
(Commission File No. 1-15024)
____________________
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
____________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:
Form 20-F: ☒
|
|
Form 40-F: ☐
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained
in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
|
|
Novartis International AG
Novartis Global Communications
CH-4002 Basel
Switzerland
http://www.novartis.com
|
MEDIA
RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG
Novartis
appoints Elizabeth Barrett as Oncology Head
|
·
|
Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further
|
|
·
|
Novartis appoints ad interim leader for its Global Drug Development organization
|
Basel, January 11, 2018 –
Novartis announced today that Elizabeth (Liz) Barrett,
currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee
of Novartis, effective February 1, 2018. She will be based in Basel. Mrs. Barrett succeeds Bruno Strigini who decided to retire
from Novartis for personal reasons.
Vasant (Vas) Narasimhan, designated CEO of Novartis, said: “Liz is a highly accomplished
and recognized oncology and people leader with an impressive record of building successful business organizations in the US, Europe
and globally. She has been instrumental in creating new commercial models, driving innovation in close partnership with research
and development and leveraging business development opportunities. Her long-time commercial pharma industry experience, marketing
skills and perspectives make Liz a great fit to further develop our oncology business.”
Mrs. Barrett said: “I feel honored to join Novartis, a recognized pioneer in the oncology
area. It is key to me to contribute to transformative advancements in oncology, and to serve in a highly impactful leadership role
to this end.”
Mrs. Barrett has held numerous leadership positions in the pharmaceutical industry as well
as in the consumer sector. In her most recent role at Pfizer, she led the oncology business through a significant period of growth
achieved in less than three years. Before joining Pfizer in 2009, she worked at Cephalon, Inc. and Johnson & Johnson. She started
her career at Kraft Foods Group, Inc. in 1984.
Mrs. Barrett is a US citizen and has lived and worked in the US and Europe. She
obtained an MBA in Marketing from the Saint Joseph’s University in Philadelphia and a BSc in Business Administration from
the University of Louisiana.
Novartis also announced today that Robert Kowalski, Pharm.D., Head of Global Regulatory Affairs,
will assume ad interim leadership of the Drug Development Organization, effective February 1, 2018. Dr. Kowalski has been Head
of Global Regulatory Affairs for Novartis since February 2016 and has played an important leadership role in securing approvals
for several breakthrough medicines including our revolutionary CAR-T therapy Kymriah™. The definitive Head of Global Drug
Development will be announced in due course.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995, . Forward-looking statements can generally be identified by words such as “effective,”
“will,” “to further develop,” or similar expressions, or by express or implied discussions regarding potential
future sales or earnings of the Novartis Group. You should not place undue reliance on these statements. Such
forward looking statements are based on our current beliefs and expectations regarding future
events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the
forward looking statements. There can be no guarantee that Novartis will be commercially successful in the future, or achieve
any particular financial results. In particular, our expectations could be affected by, among other things: regulatory actions
or delays or government regulation generally; the potential that the strategic benefits, synergies or opportunities expected from
the significant reorganizations of recent years may not be realized or may take longer to realize than expected; the uncertainties
inherent in the research and development of new healthcare products; our ability to obtain or maintain proprietary intellectual
property protection on key products; safety, quality or manufacturing issues; global trends toward health care cost containment,
including government, payor and general public pricing and reimbursement pressures; uncertainties regarding actual or potential
legal proceedings; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press release as of this date
and
does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address
the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to
best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading
positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout
the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent
associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please
contact media.relations@novartis.com
# # #
Novartis Media Relations
|
|
Central media line: +41 61 324 2200
|
|
E-mail: media.relations@novartis.com
|
|
|
|
Paul Barrett
|
Markus Jaggi
|
Novartis Global Media Relations
|
Novartis Media Relations Switzerland
|
+41 61 324 7999 (direct)
|
+41 61 324 9577 (direct)
|
+41 79 797 8137 (mobile)
|
+41 79 673 7433 (mobile)
|
paul.barrett@novartis.com
|
markus.jaggi@novartis.com
|
|
|
Eric Althoff
|
Satoshi Sugimoto
|
Novartis Global Media Relations
|
Novartis Media Relations Switzerland
|
+41 61 324 7999 (direct)
|
+41 61 324 6129
|
+41 79 593 4202 (mobile)
|
+41 79 619 2035
|
eric.althoff@novartis.com
|
satoshi_jean.sugimoto@novartis.com
|
|
|
Antonio Ligi
|
|
Novartis Global Media Relations
|
|
+41 61 324 1374 (direct)
|
|
+41 79 723 3681 (mobile)
|
|
antonio.ligi@novartis.com
|
|
Novartis Investor Relations
|
Central investor relations line: +41 61 324 7944
|
E-mail: investor.relations@novartis.com
|
Central
|
|
North America
|
|
Samir Shah
|
+41 61 324 7944
|
Richard Pulik
|
+1 212 830 2448
|
Pierre-Michel Bringer
|
+41 61 324 1065
|
Cory Twining
|
+1 212 830 2417
|
Thomas Hungerbuehler
|
+41 61 324 8425
|
|
|
Isabella Zinck
|
+41 61 324 7188
|
|
|
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Novartis AG
|
|
|
|
|
|
|
|
|
|
Date: January 11, 2018
|
By:
|
/s/ PAUL
PENEPENT
|
|
|
Name:
|
Paul Penepent
|
|
|
Title:
|
Head Group Financial Reporting and
Accounting
|
Novartis Ag Basel Namen ... (PK) (USOTC:NVSEF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novartis Ag Basel Namen ... (PK) (USOTC:NVSEF)
Historical Stock Chart
From Jul 2023 to Jul 2024